Basic Information
RNALocate ID: | RLID:11002771 |
RNA Symbol: | hsa-miR-429 |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-429 |
RNA ID: | miRBase:MIMAT0001536 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:11002768 | Exosome | Serum | 18589210 |
RLID:11002769 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11002770 | Exosome | Brain tissue | 23382797 |
RLID-D:11000139 | Exosome | Breast milk|Colon tissue|Seminal fluid|Tongue tissue | |
RLID-D:11000452 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-mir-429 | Oral squamous cell carcinoma | MNDR-E-MI-49322 |
MNDR | hsa-miR-429 | Oral squamous cell carcinoma | MNDR-E-MI-49323 |
MNDR | hsa-miR-429 | Large cell neuroendocrine cancer | MNDR-E-MI-49324 |
MNDR | hsa-miR-429 | High-grade serous ovarian carcinoma | MNDR-E-MI-49325 |
MNDR | hsa-miR-429 | Uterine corpus endometrial carcinoma | MNDR-E-MI-49326 |
MNDR | hsa-mir-429 | Immunoglobulin a deficiency | MNDR-E-MI-49327 |
MNDR | hsa-mir-429 | Non-hodgkin lymphoma somatic | MNDR-E-MI-49328 |
MNDR | hsa-miR-429 | Estrogen-receptor positive breast cancer | MNDR-E-MI-49329 |
MNDR | hsa-miR-429 | Estrogen-receptor negative breast cancer | MNDR-E-MI-49330 |
MNDR | hsa-miR-429 | Progesterone-receptor positive breast cancer | MNDR-E-MI-49331 |
MNDR | hsa-miR-429 | Progesterone-receptor negative breast cancer | MNDR-E-MI-49332 |
MNDR | hsa-miR-429 | Her2-receptor positive breast cancer | MNDR-E-MI-49333 |
MNDR | hsa-miR-429 | Breast cancer luminal | MNDR-E-MI-49334 |
MNDR | hsa-mir-429 | Colorectal carcinoma | MNDR-E-MI-49335 |
MNDR | hsa-mir-429 | Fatty liver non-alcoholic | MNDR-E-MI-49336 |
MNDR | hsa-mir-429 | Prostate cancer | MNDR-E-MI-49337 |
MNDR | hsa-mir-429 | Leukemia/lymphoma chronic b-cell | MNDR-E-MI-49338 |
MNDR | hsa-miR-429 | Hirschsprung disease | MNDR-E-MI-49339 |
MNDR | hsa-mir-429 | Gastric cancer | MNDR-E-MI-49340 |
MNDR | hsa-miR-429 | Gastric cancer | MNDR-E-MI-49341 |
MNDR | hsa-miR-429 | Alzheimer disease | MNDR-E-MI-49342 |
MNDR | hsa-mir-429 | Bladder cancer | MNDR-E-MI-49343 |
MNDR | hsa-miR-429 | Bladder cancer | MNDR-E-MI-49344 |
MNDR | hsa-mir-429 | Carcinoma esophageal | MNDR-E-MI-49345 |
MNDR | hsa-miR-429 | Gilles de la tourette syndrome | MNDR-E-MI-49346 |
MNDR | hsa-mir-429 | Nephrosclerosis | MNDR-E-MI-49347 |
MNDR | hsa-mir-429 | Cardiomyopathy dilated | MNDR-E-MI-49348 |
MNDR | hsa-miR-429 | Lung cancer | MNDR-E-MI-49349 |
MNDR | hsa-mir-429 | Lung cancer | MNDR-E-MI-49350 |
MNDR | hsa-mir-429 | Endometrial cancer | MNDR-E-MI-49351 |
MNDR | hsa-miR-429 | Endometrial cancer | MNDR-E-MI-49352 |
MNDR | hsa-mir-429 | Azoospermia | MNDR-E-MI-49353 |
MNDR | hsa-miR-429 | Parkinson disease | MNDR-E-MI-49354 |
MNDR | hsa-miR-429 | Machado-joseph disease | MNDR-E-MI-49355 |
MNDR | hsa-miR-429 | Basal-like breast cancer | MNDR-E-MI-49356 |
MNDR | hsa-mir-429 | Breast cancer | MNDR-E-MI-49357 |
MNDR | hsa-mir-429 | Cancer | MNDR-E-MI-49358 |
MNDR | hsa-miR-429 | Cancer | MNDR-E-MI-49359 |
MNDR | hsa-miR-429 | Thyroid cancer | MNDR-E-MI-49360 |
MNDR | hsa-miR-429 | Pituitary neoplasms | MNDR-E-MI-49361 |
MNDR | hsa-mir-429 | Pancreatic cancer | MNDR-E-MI-49362 |
MNDR | hsa-miR-429 | Pancreatic cancer | MNDR-E-MI-49363 |
MNDR | hsa-mir-429 | Malignant melanoma | MNDR-E-MI-49364 |
MNDR | hsa-miR-429 | Melanoma | MNDR-E-MI-49365 |
MNDR | hsa-miR-429 | Rectum adenocarcinoma | MNDR-E-MI-49366 |
MNDR | hsa-mir-429 | Nephroblastoma | MNDR-E-MI-49367 |
MNDR | hsa-miR-429 | Nephroblastoma | MNDR-E-MI-49368 |
MNDR | hsa-miR-429 | Colon cancer | MNDR-E-MI-49369 |
MNDR | hsa-mir-429 | Colon cancer | MNDR-E-MI-49370 |
MNDR | hsa-miR-429 | Colon adenocarcinoma | MNDR-E-MI-49371 |
MNDR | hsa-mir-429 | Ovarian cancer | MNDR-E-MI-49372 |
MNDR | hsa-miR-429 | Ovarian cancer | MNDR-E-MI-49373 |
MNDR | hsa-mir-429 | Adenocarcinoma endometrial | MNDR-E-MI-49374 |
MNDR | hsa-miR-429 | Endometrial endometrioid carcinoma | MNDR-E-MI-49375 |
MNDR | hsa-mir-429 | Endometriosis | MNDR-E-MI-49376 |
MNDR | hsa-mir-429 | Glomerulonephritis | MNDR-E-MI-49377 |
MNDR | hsa-mir-429 | Iga glomerulonephritis | MNDR-E-MI-49378 |
MNDR | hsa-mir-429 | Adenocarcinoma | MNDR-E-MI-49379 |
MNDR | hsa-miR-429 | Carcinoma ductal breast | MNDR-E-MI-49380 |
MNDR | hsa-mir-429 | Glioblastoma | MNDR-E-MI-49381 |
MNDR | hsa-mir-429 | Astrocytoma | MNDR-E-MI-49382 |
MNDR | hsa-mir-429 | Glioma | MNDR-E-MI-49383 |
MNDR | hsa-miR-429 | Malignant glioma | MNDR-E-MI-49384 |
MNDR | hsa-miR-429 | Temporal lobe epilepsy | MNDR-E-MI-49385 |
MNDR | hsa-mir-429 | Osteosarcoma | MNDR-E-MI-49386 |
MNDR | hsa-mir-429 | Mesenchymal cancer | MNDR-E-MI-49387 |
MNDR | hsa-miR-429 | Pediatric osteosarcoma | MNDR-E-MI-49388 |
MNDR | hsa-miR-429 | Liposarcoma | MNDR-E-MI-49389 |
MNDR | hsa-miR-429 | Breast carcinoma | MNDR-E-MI-49390 |
MNDR | hsa-mir-429 | Adenocarcinoma pancreatic ductal | MNDR-E-MI-49391 |
MNDR | hsa-miR-429 | Liver cancer | MNDR-E-MI-49392 |
MNDR | hsa-mir-429 | Liver neoplasms | MNDR-E-MI-49393 |
MNDR | hsa-miR-429 | Cervical adenocarcinoma | MNDR-E-MI-49394 |
MNDR | hsa-miR-429 | Gastric adenocarcinoma | MNDR-E-MI-49395 |
MNDR | hsa-miR-429 | Cervical squamous cell carcinoma | MNDR-E-MI-49396 |
MNDR | hsa-miR-429 | Pituitary adenoma | MNDR-E-MI-49397 |
MNDR | hsa-miR-429 | Lung squamous cell carcinoma | MNDR-E-MI-49398 |
MNDR | hsa-mir-429 | Carcinoma lung non-small-cell | MNDR-E-MI-49399 |
MNDR | hsa-miR-429 | Carcinoma lung non-small-cell | MNDR-E-MI-49400 |
MNDR | hsa-mir-429 | Lung adenocarcinoma | MNDR-E-MI-49401 |
MNDR | hsa-miR-429 | Lung adenocarcinoma | MNDR-E-MI-49402 |
MNDR | hsa-miR-429 | Thyroid carcinoma | MNDR-E-MI-49403 |
MNDR | hsa-miR-429 | Papillary thyroid cancer | MNDR-E-MI-49404 |
MNDR | hsa-miR-429 | Ovarian carcinoma | MNDR-E-MI-49405 |
MNDR | hsa-miR-429 | Bladder urothelial carcinoma | MNDR-E-MI-49406 |
MNDR | hsa-mir-429 | Cervical cancer | MNDR-E-MI-49407 |
MNDR | hsa-mir-429 | Carcinoma renal cell | MNDR-E-MI-49408 |
MNDR | hsa-miR-429 | Carcinoma renal cell | MNDR-E-MI-49409 |
MNDR | hsa-miR-429 | Kidney renal papillary cell carcinoma | MNDR-E-MI-49410 |
MNDR | hsa-miR-429 | Clear cell renal cell carcinoma | MNDR-E-MI-49411 |
MNDR | hsa-miR-429 | Biliary tract cancer | MNDR-E-MI-49412 |
MNDR | hsa-miR-429 | Intrahepatic cholangiocarcinoma | MNDR-E-MI-49413 |
MNDR | hsa-miR-429 | Cholangiocarcinoma | MNDR-E-MI-49414 |
MNDR | hsa-miR-429 | Esophageal cancer | MNDR-E-MI-49415 |
MNDR | hsa-mir-429 | Carcinoma ehrlich tumor | MNDR-E-MI-49416 |
MNDR | hsa-miR-429 | Lung small cell carcinoma | MNDR-E-MI-49417 |
MNDR | hsa-miR-429 | Gastric carcinoma | MNDR-E-MI-49418 |
MNDR | hsa-miR-429 | Testicular germ cell cancer | MNDR-E-MI-49419 |
MNDR | hsa-mir-429 | Heart failure | MNDR-E-MI-49420 |
MNDR | hsa-miR-429 | Breast invasive carcinoma | MNDR-E-MI-49421 |
MNDR | hsa-mir-429 | Carcinoma hepatocellular | MNDR-E-MI-49422 |
MNDR | hsa-miR-429 | Hepatocellular carcinoma | MNDR-E-MI-49423 |
MNDR | hsa-miR-429 | Retinoblastoma | MNDR-E-MI-49424 |
MNDR | hsa-mir-429 | Leukemia chronic myeloid | MNDR-E-MI-49425 |
MNDR | hsa-miR-429 | Ulcerative colitis | MNDR-E-MI-49426 |
MNDR | hsa-mir-429 | Mouth neoplasms | MNDR-E-MI-49427 |
MNDR | hsa-miR-429 | Crohn disease | MNDR-E-MI-49428 |
MNDR | hsa-miR-429 | Tonsil cancer | MNDR-E-MI-49429 |
MNDR | hsa-mir-429 | Systemic lupus erythematosus | MNDR-E-MI-49430 |
MNDR | hsa-mir-429 | Leukemia acute myeloid | MNDR-E-MI-49431 |
MNDR | hsa-mir-429 | Barrett's esophagus | MNDR-E-MI-49432 |
MNDR | hsa-mir-429 | Colorectal cancer | MNDR-E-MI-49433 |
MNDR | hsa-miR-429 | Colorectal cancer | MNDR-E-MI-49434 |
MNDR | hsa-miR-429 | Nasopharynx carcinoma | MNDR-E-MI-49435 |
MNDR | hsa-miR-429 | Ovarian epithelial cancer | MNDR-E-MI-49436 |
MNDR | hsa-mir-429 | Helplessness learned | MNDR-E-MI-49437 |
MNDR | hsa-miR-429 | Nasopharyngeal cancer | MNDR-E-MI-49438 |
MNDR | hsa-mir-429 | Myocardial ischemia | MNDR-E-MI-49439 |
MNDR | hsa-miR-429 | Breast cancer her3+ negative | MNDR-E-MI-49440 |
MNDR | hsa-miR-429 | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-49441 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | BAP1 | Homo sapiens | RR00211603 |
TOP